Molecular Partners AG (0QXX.L)
CHF 3.27
(4.15%)
CHF 3.27
(4.15%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -183.23 Million CHF | -120.51% |
| 2022 | -83.09 Million CHF | -26.34% |
| 2021 | -65.77 Million CHF | 48.01% |
| 2020 | -126.5 Million CHF | -72.9% |
| 2019 | -73.16 Million CHF | 26.06% |
| 2018 | -98.95 Million CHF | 24.64% |
| 2017 | -131.31 Million CHF | 12.3% |
| 2016 | -149.73 Million CHF | 23.36% |
| 2015 | -195.36 Million CHF | -3.71% |
| 2014 | -188.38 Million CHF | -95.97% |
| 2013 | -96.12 Million CHF | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -170.78 Million CHF | 6.8% |
| 2024 Q3 | -64.53 Million CHF | 58.65% |
| 2024 Q2 | -156.07 Million CHF | 8.61% |
| 2023 Q1 | -69.37 Million CHF | 16.51% |
| 2023 Q3 | -64.44 Million CHF | -9.25% |
| 2023 Q2 | -58.99 Million CHF | 14.97% |
| 2023 Q4 | -183.23 Million CHF | -184.32% |
| 2023 FY | -183.23 Million CHF | -120.51% |
| 2022 Q3 | -64.55 Million CHF | 41.04% |
| 2022 Q1 | -136.27 Million CHF | -107.19% |
| 2022 FY | -83.09 Million CHF | -26.34% |
| 2022 Q4 | -83.09 Million CHF | -28.72% |
| 2022 Q2 | -109.49 Million CHF | 19.65% |
| 2021 Q4 | -65.77 Million CHF | 14.1% |
| 2021 FY | -65.77 Million CHF | 48.01% |
| 2021 Q3 | -76.57 Million CHF | 36.16% |
| 2021 Q2 | -119.93 Million CHF | 13.51% |
| 2021 Q1 | -138.67 Million CHF | -9.63% |
| 2020 Q1 | 95.08 Million CHF | 229.95% |
| 2020 FY | -126.5 Million CHF | -72.9% |
| 2020 Q2 | -45.4 Million CHF | -147.75% |
| 2020 Q4 | -126.5 Million CHF | 0.0% |
| 2019 FY | -73.16 Million CHF | 26.06% |
| 2019 Q3 | -74.43 Million CHF | -15.46% |
| 2019 Q2 | -64.46 Million CHF | 1.91% |
| 2019 Q1 | -65.72 Million CHF | 33.59% |
| 2019 Q4 | -73.16 Million CHF | 1.7% |
| 2018 Q4 | -98.95 Million CHF | 0.0% |
| 2018 Q3 | -98.95 Million CHF | -6.79% |
| 2018 Q1 | -92.66 Million CHF | 29.43% |
| 2018 Q2 | -92.66 Million CHF | 0.0% |
| 2018 FY | -98.95 Million CHF | 24.64% |
| 2017 Q1 | 180.22 Million CHF | 220.36% |
| 2017 FY | -131.31 Million CHF | 12.3% |
| 2017 Q4 | -131.31 Million CHF | 0.0% |
| 2017 Q3 | -131.31 Million CHF | -10.76% |
| 2017 Q2 | -118.55 Million CHF | -165.78% |
| 2016 Q3 | 196.34 Million CHF | 211.07% |
| 2016 Q2 | -176.78 Million CHF | -182.07% |
| 2016 Q1 | 215.39 Million CHF | 210.25% |
| 2016 FY | -149.73 Million CHF | 23.36% |
| 2016 Q4 | -149.73 Million CHF | -176.26% |
| 2015 Q4 | -195.36 Million CHF | 0.0% |
| 2015 Q2 | -175.63 Million CHF | -193.23% |
| 2015 FY | -195.36 Million CHF | -3.71% |
| 2015 Q1 | 188.38 Million CHF | 200.0% |
| 2014 Q4 | -188.38 Million CHF | 0.0% |
| 2014 FY | -188.38 Million CHF | -95.97% |
| 2014 Q1 | 96.12 Million CHF | 0.0% |
| 2013 FY | -96.12 Million CHF | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Relief Therapeutics Holding AG | -10.24 Million CHF | -1688.551% |
| Tecan Group AG | 183.12 Million CHF | 200.059% |
| Santhera Pharmaceuticals Holding AG | -5.3 Million CHF | -3352.091% |
| Basilea Pharmaceutica AG | 116.11 Million CHF | 257.804% |
| Bachem Holding AG | -157.32 Million CHF | -16.471% |
| Siegfried Holding AG | 468.63 Million CHF | 139.1% |